Repligen AIDS vaccine
Executive Summary
Company begins Phase I trial with a potential HIV therapeutic vaccine, RP400c immunogen, at the University of Colorado Health Sciences Center, Repligen announces June 7. The RP400c candidate vaccine contains the HIV V3 loop segment, which is the primary target for antibodies that neutralize the virus. Repligen says it has modified its ongoing agreement with Merck for the development of a prophylactic HIV vaccine to allow Repligen to conduct independently the initial studies of RP400c. After that, Merck has the option to compensate Repligen for development costs and become a codeveloper and copromoter of the vaccine candidate.
You may also be interested in...
Part D Discount Liability Coming Into Focus: CMS Releases Drug Cost Data
Newly released Medicare Part D data sheds light on the sales hit that branded pharmaceutical manufacturers will face when the coverage gap discount program gets under way in 2011
FDA Skin Infections Guidance Spurs Debate On Endpoint Relevance
FDA appears headed for a showdown with clinicians and the pharmaceutical industry over the proposed new clinical trial endpoints for acute bacterial skin and skin structure infections, the guidance's approach for justifying a non-inferiority margin and proposed changes in the types of patients that should be enrolled in trials
Shire Hopes To Sow Future Deals With $50M Venture Fund
Specialty drug maker Shire has quietly begun scouting deals with a brand-new $50 million venture fund, the latest of several in-house investment arms to launch with their parent company's pipelines, not profits, as the measure of their worth